[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:metastatic-malignant-neoplasm":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":84,"states":85},"Metastatic Malignant Neoplasm",12,10,[8,16,22,29,34,40,46,52,58,65,71,78],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06058988","Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer",[12],"Phase 2","RECRUITING","2026-08-26T02:18:00.873391Z","2026-05-05T02:43:29.583696Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06630845","Comparison of Whole Body DWI to FDG PET",[],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:28.711002Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05065736","Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer",[26],"Early Phase 1","2026-08-03T02:40:44.217164Z","2026-05-05T02:43:28.294864Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":14,"content_modified":33},"NCT05100342","Prospective Validation of a Points Score System Predicting 30-day Survival",[],"2026-05-13T02:55:06.283355Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT04085029","Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry",[],"2026-08-26T02:18:01.700186Z","2026-05-13T02:55:06.233408Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":44,"content_modified":45},"NCT00280202","Detection of Genetic Markers of Lung Cancer",[],"2026-08-26T02:15:25.633039Z","2026-05-13T02:55:06.033277Z",{"nct_id":47,"title":48,"phases":49,"status":13,"updated_at":50,"content_modified":51},"NCT04842266","IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures",[],"2026-08-26T02:18:33.598205Z","2026-05-13T02:55:06.272444Z",{"nct_id":53,"title":54,"phases":55,"status":13,"updated_at":56,"content_modified":57},"NCT04098146","Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis",[],"2026-08-26T02:18:23.582895Z","2026-05-13T02:55:06.241291Z",{"nct_id":59,"title":60,"phases":61,"status":13,"updated_at":63,"content_modified":64},"NCT06085716","Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers",[62],"Phase 2\u002FPhase 3","2026-08-26T02:17:55.355429Z","2026-05-05T02:43:27.916579Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT05349227","Comprehensive Outcomes for After Cancer Health",[],"2026-08-26T02:19:02.550788Z","2026-05-29T15:36:40.172941Z",{"nct_id":72,"title":73,"phases":74,"status":75,"updated_at":76,"content_modified":77},"NCT07594431","Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:05.813655Z","2026-05-29T15:36:40.204169Z",{"nct_id":79,"title":80,"phases":81,"status":75,"updated_at":82,"content_modified":83},"NCT07586046","Defining the Ablative Dose for Y-90 TARE",[12],"2026-08-26T02:18:05.435729Z","2026-05-29T15:36:40.197904Z",[],[86,90],{"state":87,"count":88,"slug":89},"New York",3,"new-york",{"state":91,"count":88,"slug":92},"Texas","texas"]